Search results for "Fibrin"

showing 10 items of 508 documents

Drugs and diseases: Summary and consensus statements of group 1. The 5th EAO Consensus Conference 2018

2018

OBJECTIVES: The task of this working group was to update the knowledge about the use of drugs and biologicals affecting healing of soft tissue and bone during implant treatment or procedures associated with it. Moreover, the impact of titanium particles and biocorrosion on complications and implant survival has been analysed. MATERIALS AND METHODS: The literature in the areas of interest (platelet concentrates, antiresorptive drugs as well as implant-host interaction) was screened using systematic reviews for the former two areas, whereas a narrative critical review was performed for the latter topic. Two manuscripts on platelet concentrates, one manuscript on antiresorptive drugs and one m…

0301 basic medicineTechnologymedicine.medical_specialtymedication-related osteonecrosis of the jawsplatelet-rich fibrin610 Medicine & healthOdontologi03 medical and health sciencesEngineering0302 clinical medicinesystematic reviewguided bone regeneration sinus floor elevationdental implantsDentistry Oral Surgery & Medicinemedicineantiresorptive drugstitanium610 Medicine & healthEngineering BiomedicalbisphosphonatesScience & Technologycorrosionbusiness.industryConsensus conferenceimplant therapyplatelet-rich plasma030206 dentistryddc:617.63. Good healthhormone replacement therapyAntiresorptive Drugs030104 developmental biologySystematic reviewGroup analysisDentistryFamily medicinealveolar ridge preservationOral SurgerybusinessLife Sciences & Biomedicineperi-implantitisClinical Oral Implants Research
researchProduct

Inflammation and the coagulation system in tuberculosis: Tissue Factor leads the dance

2016

Mycobacterium tuberculosis, the causative agent of tuberculosis, drives the formation of granulomas, structures in which both immune cells and the bacterial pathogen cohabit. The most abundant cells in granulomas are macrophages, which contribute as both cells with bactericidal activity and as targets for M. tuberculosis infection and proliferation during the entire course of infection. The mechanisms and factors involved in the regulation and control of macrophage microenvironment-specific polarization and plasticity are not well understood, as some granulomas are able to control bacteria growth and others fail to do so, permitting bacterial spread. In this issue of the European Journal of…

0301 basic medicineTuberculosisMacrophageTuberculosiImmunologyInflammationMacrophages; Mycobacterium tuberculosis; Tissue Factor; Tuberculosis; Animals; Bacteremia; Cell Differentiation; Fibrin; Host-Pathogen Interactions; Humans; Immunity Innate; Lung; Macrophages; Mice; Mice Knockout; Mycobacterium tuberculosis; Pneumonia; Thromboplastin; Tuberculoma; Tuberculosis Pulmonary; Blood Coagulation; Immunology; Immunology and Allergy; Medicine (all)BacteremiaMycobacterium tuberculosiThromboplastinMycobacterium tuberculosis03 medical and health sciencesTissue factorMiceImmune systemImmunitymedicineMacrophageImmunology and AllergyAnimalsHumansTuberculomaBlood CoagulationLungTuberculosis PulmonaryMice KnockoutFibrinCord factorbiologyAnimalMedicine (all)MacrophagesCell DifferentiationMycobacterium tuberculosisPneumoniabiology.organism_classificationmedicine.diseaseImmunity Innate3. Good healthTissue FactorHost-Pathogen Interaction030104 developmental biologyImmunologyHost-Pathogen Interactionsmedicine.symptomHumanEuropean Journal of Immunology
researchProduct

Thrombo-Inflammation in Cardiovascular Disease

2020

AbstractThrombo-inflammation describes the complex interplay between blood coagulation and inflammation that plays a critical role in cardiovascular diseases. The third Maastricht Consensus Conference on Thrombosis assembled basic, translational, and clinical scientists to discuss the origin and potential consequences of thrombo-inflammation in the etiology, diagnostics, and management of patients with cardiovascular disease, including myocardial infarction, stroke, and peripheral artery disease. This article presents a state-of-the-art reflection of expert opinions and consensus recommendations regarding the following topics: (1) challenges of the endothelial cell barrier; (2) circulating …

0301 basic medicineVENOUS THROMBOSISmedicine.medical_specialtypulmonary embolismNeutrophilsIschemiaISCHEMIA-REPERFUSION INJURYDisease030204 cardiovascular system & hematologyCATHETER-DIRECTED THROMBOLYSIS03 medical and health sciences0302 clinical medicinePERIPHERAL ARTERY-DISEASEMedicineAnimalsHumansPlateletMyocardial infarctionDEEP-VEIN THROMBOSIScoagulationIntensive care medicineStrokeBlood CoagulationExpert Testimonythrombosisbusiness.industryACUTE CORONARY SYNDROMESNEUTROPHIL EXTRACELLULAR TRAPSHematologyNeutrophil extracellular trapsVenous ThromboembolismACTIVATABLE FIBRINOLYSIS INHIBITORmedicine.diseaseAtherosclerosisThrombosisstrokeImmunity Innate3. Good healthVenous thrombosis030104 developmental biologymyocardial infarctionTISSUE FACTORCardiovascular DiseasesinflammationplateletsEndothelium VascularbusinessSUBCLINICAL LEAFLET THROMBOSISThrombosis and Haemostasis
researchProduct

Age-dependent control of collagen-dependent platelet responses by thrombospondin-1 : Comparative analysis of platelets from neonates, children, adole…

2021

Platelet function is developmentally regulated. Healthy neonates do not spontaneously bleed, but their platelets are hypo-reactive to several agonists. The mechanisms underlying immature platelet function in neonates are incompletely understood. This critical issue remains challenging for the establishment of age-specific reference ranges. In this study, we evaluated platelet reactivity of five pediatric age categories, ranging from healthy full-term neonates up to adolescents (11–18 years) in comparison to healthy adults (&gt

0301 basic medicinecollagenAgingMedizin030204 cardiovascular system & hematologyImmature PlateletThrombospondin 10302 clinical medicinePlateletBiology (General)ChildSpectroscopyCD63medicine.diagnostic_testGeneral MedicineComputer Science ApplicationsAdenosine DiphosphateChemistryplateletsAgonistAdultBlood Plateletsmedicine.medical_specialtyAdolescentmedicine.drug_classQH301-705.5Receptors Proteinase-ActivatedCatalysisExocytosisArticleFlow cytometryInorganic Chemistry03 medical and health sciencesInternal medicineThrombospondin 1Crotalid VenomsmedicineHumansLectins C-TypePlatelet activationPhysical and Theoretical Chemistrythrombospondin-1Molecular BiologyQD1-999business.industryflow cytometryOrganic ChemistryInfant NewbornFibrinogen bindingInfantPlatelet Activationreference rangesneonates030104 developmental biologyEndocrinologybusinessPeptides
researchProduct

Engineering of Human Skeletal Muscle With an Autologous Deposited Extracellular Matrix

2018

Adult skeletal muscle progenitor cells can be embedded in an extracellular matrix (ECM) and tissue-engineered to form bio-artificial muscles (BAMs), composed of aligned post-mitotic myofibers. The ECM proteins which have been used most commonly are collagen type I and fibrin. Fibrin allows for in vitro vasculogenesis, however, high concentrations of fibrinolysis inhibitors are needed to inhibit degradation of the ECM and subsequent loss of BAM tissue structure. For in vivo implantation, fibrinolysis inhibition may prove difficult or even harmful to the host. Therefore, we adapted in vitro culture conditions to enhance the deposition of de novo synthesized collagen type I gradually replacing…

0301 basic medicinecollagenPhysiologyextracellular matrix02 engineering and technologyFibrinlcsh:PhysiologyExtracellular matrix03 medical and health sciencesHydroxyprolinechemistry.chemical_compoundTissue cultureVasculogenesisTissue engineeringPhysiology (medical)medicinefibrinskeletal muscleOriginal Researchbiologylcsh:QP1-981ChemistrySkeletal muscleviscoelastic propertiesfood and beveragesAnatomy021001 nanoscience & nanotechnologyAscorbic acidCell biology030104 developmental biologymedicine.anatomical_structuretissue engineeringbiology.protein0210 nano-technology
researchProduct

Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.

2020

AbstractCoronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct…

0301 basic medicinecoronavirusAnti-Inflammatory AgentsReview Article030204 cardiovascular system & hematologymedicine.disease_causelaw.inventioncovid190302 clinical medicineRandomized controlled triallawAntithromboticPandemicViralanticoagulationCoronavirusGlycosaminoglycansAnimals; Anti-Inflammatory Agents; Anticoagulants; Antiviral Agents; Betacoronavirus; Coronavirus Infections; Fibrinolytic Agents; Glycosaminoglycans; Hemostasis; Humans; Inflammation; Pandemics; Platelet Aggregation Inhibitors; Pneumonia Viral; Thrombosiscoronavirus 2immunomodulatorHematologyHeparinThrombosisantithrombinCoronavirus Infectionsmedicine.drugmedicine.medical_specialtyPneumonia Viralcoronavirus disease 2019 thrombosis inflammation fibrinolytic therapy anticoagulation immunomodulator antithrombin thrombomodulinAntiviral Agents03 medical and health sciencescoronavirus disease 2019BetacoronavirusFibrinolytic AgentsmedicineAnimalsHumansthrombosis COVID-19 coronavirusDosingIntensive care medicinePandemicsthrombosisInflammationHemostasisbusiness.industrySARS-CoV-2AnticoagulantsCOVID-19ThrombosisPneumoniathrombomodulinmedicine.diseaseReview articleCOVID-19 Drug Treatment030104 developmental biologyinflammationfibrinolytic therapybusinessPlatelet Aggregation InhibitorsThrombosis and haemostasis
researchProduct

Tissue factor prothrombotic activity is regulated by integrin-arf6 trafficking

2017

Objective— Coagulation initiation by tissue factor (TF) is regulated by cellular inhibitors, cell surface availability of procoagulant phosphatidylserine, and thiol-disulfide exchange. How these mechanisms contribute to keeping TF in a noncoagulant state and to generating prothrombotic TF remain incompletely understood. Approach and Results— Here, we study the activation of TF in primary macrophages by a combination of pharmacological, genetic, and biochemical approaches. We demonstrate that primed macrophages effectively control TF cell surface activity by receptor internalization. After cell injury, ATP signals through the purinergic receptor P2rx7 induce release of TF + microvesicles. T…

0301 basic medicinedynaminsIntegrin alpha4CellCardiorespiratory Medicine and Haematology030204 cardiovascular system & hematologyIntegrin alpha4beta1Inbred C57BLTransgenicMicechemistry.chemical_compound0302 clinical medicineAdenosine TriphosphateCell-Derived MicroparticlesReceptors2.1 Biological and endogenous factorsfibrinGene Knock-In TechniquesAetiologyPhospholipidsTumorbiologyChemistryADP-Ribosylation FactorsHematologyPhosphatidylserineCell biologyProtein Transportmedicine.anatomical_structurePhenotypeProteomeextracellular vesiclesCardiology and Cardiovascular MedicinePurinergic P2X7BiotechnologySignal TransductionGenotypeproteomeClinical SciencesIntegrinMice TransgenicFactor VIIaTransfectionExtracellular vesiclesFibrinArticleCell LineThromboplastin03 medical and health sciencesTissue factorCell Line TumormedicineAnimalsHumansBlood CoagulationMacrophagesThrombosisMice Inbred C57BL030104 developmental biologyCardiovascular System & HematologyADP-Ribosylation Factor 6biology.proteinReceptors Purinergic P2X7
researchProduct

Effect of Whole-Body Cryotherapy on Morphological, Rheological and Biochemical Indices of Blood in People with Multiple Sclerosis

2021

The aim of this study was to examine and assess the impact of a series of 20 whole-body cryotherapy (WBC) treatments on the biochemical and rheological indices of blood in people with multiple sclerosis. In this prospective controlled study, the experimental group consisted of 15 women aged 34–55 (mean age, 41.53 ± 6.98 years) with diagnosed multiple sclerosis who underwent a series of whole-body cryotherapy treatments. The first control group consisted of 20 women with diagnosed multiple sclerosis. This group had no intervention in the form of whole-body cryotherapy. The second control group consisted of 15 women aged 30–49 years (mean age, 38.47 ± 6.0 years) without neurological diseases …

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatmentBlood countCryotherapyHematocritmultiple sclerosisFibrinogenGastroenterologyArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicineblood rheologyblood morphologymedicine.diagnostic_testbusiness.industryMultiple sclerosisRWhole body cryotherapyGeneral MedicineVenous bloodmedicine.diseasewhole-body cryotherapy030104 developmental biologyMedicineHemoglobinbusiness030217 neurology & neurosurgerymedicine.drugJournal of Clinical Medicine
researchProduct

Deficiency of plasminogen activator inhibitor 2 in plasma of patients with hereditary angioedema with normal C1 inhibitor levels

2016

Background Hereditary angioedema with normal C1 inhibitor levels (HAE-N) is associated with a Factor XII mutation in 30% of subjects; however, the role of this mutation in the pathogenesis of angioedema is unclear. Objective We sought evidence of abnormalities in the pathways of bradykinin formation and bradykinin degradation in the plasma of patients with HAE-N both with and without the mutation. Methods Bradykinin was added to plasma, and its rate of degradation was measured by using ELISA. Plasma autoactivation was assessed by using a chromogenic assay of kallikrein formation. Plasminogen activator inhibitors (PAIs) 1 and 2 were also measured by means of ELISA. Results PAI-1 levels varie…

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatmentImmunologyBradykinin030204 cardiovascular system & hematologyArticleC1-inhibitor03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineFibrinolysismedicineImmunology and AllergyFactor XIIAngioedemabiologybusiness.industryKallikreinmedicine.disease030104 developmental biologyEndocrinologychemistryPlasminogen activator inhibitor-1Hereditary angioedemabiology.proteinmedicine.symptombusinessJournal of Allergy and Clinical Immunology
researchProduct

Specialized regulatory T cells control venous blood clot resolution through SPARC.

2020

Abstract The cells and mechanisms involved in blood clot resorption are only partially known. We show that regulatory T cells (Tregs) accumulate in venous blood clots and regulate thrombolysis by controlling the recruitment, differentiation and matrix metalloproteinase (MMP) activity of monocytes. We describe a clot Treg population that forms the matricellular acid– and cysteine-rich protein SPARC (secreted protein acidic and rich in cysteine) and show that SPARC enhances monocyte MMP activity and that SPARC+ Tregs are crucial for blood clot resorption. By comparing different treatment times, we define a therapeutic window of Treg expansion that accelerates clot resorption.

0301 basic medicinemedicine.medical_treatmentImmunologyPopulation030204 cardiovascular system & hematologyMatrix metalloproteinaseBiochemistryT-Lymphocytes RegulatoryMonocytes03 medical and health sciences0302 clinical medicinemedicineAnimalsOsteonectinThrombuseducationVenous Thrombosiseducation.field_of_studyChemistryMonocyteFibrinolysisCell BiologyHematologyVenous bloodThrombolysismedicine.diseaseMatrix MetalloproteinasesResorptionCell biologyMice Inbred C57BL030104 developmental biologymedicine.anatomical_structureCysteineBlood
researchProduct